NH TherAguix SAS

NH TherAguix SAS develops innovative nanomedicine technologies to enhance precision radiotherapy for cancer treatment, primarily through its proprietary AGuIX® nanoparticle. Founded in 2015 in France, NH TherAguix SAS focuses on the advancement of nanomedicine for cancer therapies. The company's CEO, Vincent Carrère, leads the organization through a pivotal phase, having successfully raised EUR 4. 06 million in Series A funding on June 3, 2021.

The total amount raised by the company is EUR 4. 06 million, with a current company valuation of EUR 33. 023 million. NH TherAguix specializes in developing innovative nanomedicine technologies aimed at enhancing precision radiotherapy for cancer treatment.

The core product, AGuIX®, is a novel nanoparticle designed to improve the efficacy of radiotherapy by targeting tumors directly, utilizing specific pharmacological properties and bio-distribution mechanisms to localize within the tumor microenvironment, potentially offering a pan-cancer solution. In 2022, NH TherAguix recorded zero revenue, with an EBITDA of EUR -6,219,521. 1. The company generates revenue through strategic partnerships and clinical trials, particularly in the oncology sector, engaging in B2B transactions with healthcare institutions and clinical research organizations for the use of AGuIX® nanoparticles.

Following its Series A funding in June 2021, NH TherAguix plans to expand its product offerings and geographic reach. The company aims to utilize the EUR 4. 06 million raised to further develop its AGuIX® nanoparticles and advance ongoing clinical trials. Target markets for expansion include Europe, North America, and Asia, where there is a significant demand for advanced cancer therapies.